Logo image of ASRT

ASSERTIO HOLDINGS INC (ASRT) Stock Fundamental Analysis

NASDAQ:ASRT - Nasdaq - US04546C2052 - Common Stock - Currency: USD

0.68  -0.01 (-1.71%)

Premarket: 0.72 +0.04 (+5.88%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ASRT. ASRT was compared to 197 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ASRT have multiple concerns. ASRT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ASRT has reported negative net income.
In the past year ASRT had a positive cash flow from operations.
In the past 5 years ASRT reported 4 times negative net income.
Of the past 5 years ASRT 4 years had a positive operating cash flow.
ASRT Yearly Net Income VS EBIT VS OCF VS FCFASRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

ASRT has a better Return On Assets (-10.69%) than 69.04% of its industry peers.
With a decent Return On Equity value of -28.21%, ASRT is doing good in the industry, outperforming 64.47% of the companies in the same industry.
Industry RankSector Rank
ROA -10.69%
ROE -28.21%
ROIC N/A
ROA(3y)-32.33%
ROA(5y)-21.33%
ROE(3y)-69.93%
ROE(5y)-52.34%
ROIC(3y)N/A
ROIC(5y)N/A
ASRT Yearly ROA, ROE, ROICASRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

Looking at the Gross Margin, with a value of 69.89%, ASRT is in the better half of the industry, outperforming 76.65% of the companies in the same industry.
In the last couple of years the Gross Margin of ASRT has declined.
The Profit Margin and Operating Margin are not available for ASRT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.36%
GM growth 5Y-6.47%
ASRT Yearly Profit, Operating, Gross MarginsASRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

3

2. Health

2.1 Basic Checks

ASRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ASRT has more shares outstanding
ASRT has more shares outstanding than it did 5 years ago.
ASRT has a worse debt/assets ratio than last year.
ASRT Yearly Shares OutstandingASRT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ASRT Yearly Total Debt VS Total AssetsASRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -2.69, we must say that ASRT is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ASRT (-2.69) is comparable to the rest of the industry.
ASRT has a debt to FCF ratio of 6.12. This is a slightly negative value and a sign of low solvency as ASRT would need 6.12 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 6.12, ASRT belongs to the best of the industry, outperforming 82.74% of the companies in the same industry.
A Debt/Equity ratio of 0.36 indicates that ASRT is not too dependend on debt financing.
ASRT has a Debt to Equity ratio (0.36) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF 6.12
Altman-Z -2.69
ROIC/WACCN/A
WACC9.81%
ASRT Yearly LT Debt VS Equity VS FCFASRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 1.66 indicates that ASRT should not have too much problems paying its short term obligations.
ASRT has a Current ratio of 1.66. This is in the lower half of the industry: ASRT underperforms 65.48% of its industry peers.
A Quick Ratio of 1.35 indicates that ASRT should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.35, ASRT is doing worse than 64.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.35
ASRT Yearly Current Assets VS Current LiabilitesASRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 77.78% over the past year.
ASRT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.22%.
ASRT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.45% yearly.
EPS 1Y (TTM)77.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)-16.22%
Revenue growth 3Y4.03%
Revenue growth 5Y-11.45%
Sales Q2Q%-18.37%

3.2 Future

Based on estimates for the next years, ASRT will show a very strong growth in Earnings Per Share. The EPS will grow by 35.26% on average per year.
Based on estimates for the next years, ASRT will show a small growth in Revenue. The Revenue will grow by 4.16% on average per year.
EPS Next Y2.43%
EPS Next 2Y28.7%
EPS Next 3Y30.49%
EPS Next 5Y35.26%
Revenue Next Year-6.19%
Revenue Next 2Y2.37%
Revenue Next 3Y2.3%
Revenue Next 5Y4.16%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ASRT Yearly Revenue VS EstimatesASRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
ASRT Yearly EPS VS EstimatesASRT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ASRT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ASRT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASRT Price Earnings VS Forward Price EarningsASRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

ASRT's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ASRT is cheaper than 91.37% of the companies in the same industry.
Industry RankSector Rank
P/FCF 10.24
EV/EBITDA -27.54
ASRT Per share dataASRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as ASRT's earnings are expected to grow with 30.49% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.7%
EPS Next 3Y30.49%

More info and screens

0

5. Dividend

5.1 Amount

ASRT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASSERTIO HOLDINGS INC

NASDAQ:ASRT (5/29/2025, 8:00:00 PM)

Premarket: 0.72 +0.04 (+5.88%)

0.68

-0.01 (-1.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners29.96%
Inst Owner Change-7.17%
Ins Owners1.17%
Ins Owner Change3.09%
Market Cap65.13M
Analysts82
Price Target2.87 (322.06%)
Short Float %5.73%
Short Ratio13.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-55.23%
Min EPS beat(2)-145.1%
Max EPS beat(2)34.64%
EPS beat(4)2
Avg EPS beat(4)-24.24%
Min EPS beat(4)-145.1%
Max EPS beat(4)36.06%
EPS beat(8)2
Avg EPS beat(8)-471.2%
EPS beat(12)5
Avg EPS beat(12)-302.18%
EPS beat(16)7
Avg EPS beat(16)-219.9%
Revenue beat(2)1
Avg Revenue beat(2)2.2%
Min Revenue beat(2)-5.64%
Max Revenue beat(2)10.04%
Revenue beat(4)2
Avg Revenue beat(4)1.25%
Min Revenue beat(4)-5.64%
Max Revenue beat(4)10.04%
Revenue beat(8)4
Avg Revenue beat(8)-2.68%
Revenue beat(12)8
Avg Revenue beat(12)0.72%
Revenue beat(16)12
Avg Revenue beat(16)2.44%
PT rev (1m)0%
PT rev (3m)-7.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-200%
EPS NY rev (1m)-23.6%
EPS NY rev (3m)-214.29%
Revenue NQ rev (1m)-0.46%
Revenue NQ rev (3m)-10.97%
Revenue NY rev (1m)-1.14%
Revenue NY rev (3m)-7.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.55
P/FCF 10.24
P/OCF 10.24
P/B 0.6
P/tB 1.75
EV/EBITDA -27.54
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)0.07
FCFY9.77%
OCF(TTM)0.07
OCFY9.77%
SpS1.24
BVpS1.13
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.69%
ROE -28.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.89%
FCFM 5.35%
ROA(3y)-32.33%
ROA(5y)-21.33%
ROE(3y)-69.93%
ROE(5y)-52.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.36%
GM growth 5Y-6.47%
F-Score4
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF 6.12
Debt/EBITDA 30.13
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion 492.42%
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.35
Altman-Z -2.69
F-Score4
WACC9.81%
ROIC/WACCN/A
Cap/Depr(3y)16.81%
Cap/Depr(5y)10.15%
Cap/Sales(3y)3.56%
Cap/Sales(5y)2.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y2.43%
EPS Next 2Y28.7%
EPS Next 3Y30.49%
EPS Next 5Y35.26%
Revenue 1Y (TTM)-16.22%
Revenue growth 3Y4.03%
Revenue growth 5Y-11.45%
Sales Q2Q%-18.37%
Revenue Next Year-6.19%
Revenue Next 2Y2.37%
Revenue Next 3Y2.3%
Revenue Next 5Y4.16%
EBIT growth 1Y-1893.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year169.51%
EBIT Next 3Y65.52%
EBIT Next 5Y43.56%
FCF growth 1Y-89.07%
FCF growth 3Y69.74%
FCF growth 5Y-21.57%
OCF growth 1Y-91.39%
OCF growth 3Y68.7%
OCF growth 5Y-21.83%